Prostate Cancer

Robert B. Den, MD, outlines the exploratory applications of the Alpha DaRT technology across the prostate and bladder cancer landscapes.

Concurrent use of an ARPI with [177Lu]Lu-PSMA-617 did not improve response rates nor overall survival in patients with ARPI-refractory mCRPC.

According to the authors, these data support the value of PSMA PET/CT in the pre-salvage radiotherapy selection process.

The agent is currently being evaluated in a phase 1/2 trial.

The ArteraAI test is now the first and only AI-powered tool to be authorized to prognosticate long-term outcomes in patients with localized prostate cancer.

HIFU was shown to be an effective and tolerable treatment option for patients with intermediate-risk localized prostate cancer.

The target action date for the application is March 6, 2026.

The phase 1 STRIKE-001 trial will evaluate KTX-2001 as both a monotherapy and in combination with darolutamide.

Data from the phase 2 EXTEND trial showed that the addition of metastasis-directed therapy to ADT improved measures of systemic disease control.

Take a look through key stories from last month, including regulatory news, trial updates, and other practice-changing advancements.

Panelists discuss how clinicians can confidently adapt to newer androgen deprivation therapy options like relugolix in combination therapies despite limited prospective data, emphasizing that oral agents simplify patient visits and provide equivalent testosterone suppression.

Panelists discuss how NCCN guidelines provide a framework for selecting appropriate androgen deprivation therapy (ADT) regimens across different disease states, with combination therapies now being standard of care rather than ADT monotherapy in most cases.

INKmune was well-tolerated across all 3 dose levels assessed.

Data showed that 1 in 6 men with GG1 prostate cancer ultimately had higher-risk disease when other clinical features were taken into account.

A recap of the FDA submissions and regulatory decisions in urology from July 2025.

ATNM-400 demonstrated improved efficacy compared with 177Lu-PSMA-617 in treatment-resistant models as well as enhanced efficacy in combination with enzalutamide.

Enzalutamide plus ADT was associated with significant improvements in rPFS and time to castration resistance compared with darolutamide plus ADT.

Panelists discuss how patient adherence to oral androgen deprivation therapy has been reliable in both clinical trials and practice, with the convenience of daily pills and portability during travel contributing to good compliance rates.

Panelists discuss how multiple pharmacologic and clinical factors influence androgen deprivation therapy selection, including mechanism of action, delivery method, patient preferences, cardiovascular risk profile, and the potential for rapid testosterone recovery.

The 500 mg regimen of abiraterone acetate demonstrated comparable anti-tumor activity and a favorable safety profile compared with the standard 1000 mg dose.

The WATER IV PCa trial is comparing first-line Aquablation therapy with radical prostatectomy for the treatment of patients with localized prostate cancer.

The new advanced annotation workflow on the UroNav System is designed to work in tandem with DynaCAD Urology to support focal therapy planning.

Panelists discuss how oral androgen deprivation therapy options like relugolix fit into current treatment strategies across multiple patient categories, offering advantages in rapid onset, quick recovery, and convenience, particularly for patients requiring short-term treatment or those with cardiovascular risk factors.

Panelists discuss how the treatment paradigm for androgen deprivation therapy is evolving from traditional injectable GnRH agonists to include oral GnRH antagonists like relugolix, which offer more rapid onset, faster recovery, and avoidance of testosterone flare.

The PRESERVE trial met its primary end point by demonstrating a negative in-field biopsy rate of 71% at 12 months.

This approval enables the use of darolutamide plus ADT with or without chemotherapy.

In both cohorts, the combination of talazoparib plus enzalutamide led to a significant improvement in overall survival vs enzalutamide alone.

Take a look back through some of the top stories from the first half of the year.

Data showed that African American men faced significant delays in treatment initiation.

The level II code A9616 will be effective starting on October 1, 2025.